Mechanism of Action of Metformin

Metformin lowers blood glucose primarily by suppressing hepatic gluconeogenesis (the synthesis of new glucose in the liver). It interacts with cellular energy metabolism, particularly within the mitochondria. Metformin can inhibit mitochondrial respiratory-chain complex I and inhibit mitochondrial glycerol-3-phosphate dehydrogenase (mGPD), altering cellular energy and redox metabolism. These effects can contribute to activation of AMP-activated protein kinase (AMPK) and suppression of hepatic gluconeogenesis.

Activated AMPK the surpasses two key enzymes involved in hepatic gluconeogenesis:

1. Phosphoenolpyruvate carboxykinase (PEPCK)
2. Glucose-6-phosphatase (G6Pase)

This will significantly slow down the de-novo synthesis of the new glucose in the liver.

Metformin also improves insulin sensitivity in the liver, adipose tissue, and skeletal muscle, increasing glucose uptake and utilization and reducing insulin resistance.

Its glucose-lowering effects are not mediated by AMPK alone. Metformin also acts through AMPK-independent mechanisms and has important effects within the gastrointestinal tract.

Key effects of the Metformin action

1. ↓ Hepatic gluconeogenesis — main effect

Metformin reduces the liver’s production of glucose from substrates such as lactate, glycerol and amino acids. This is the major mechanism responsible for its glucose-lowering effect.

2. ↑ Insulin sensitivity

Metformin improves insulin-mediated glucose uptake, particularly in skeletal muscle, and reduces insulin resistance.

3. Mitochondrial effects

Metformin can inhibit mitochondrial respiratory-chain complex I, reducing cellular ATP production and increasing the AMP/ATP ratio.

4. AMPK activation

The resulting changes in cellular energy status can activate AMP-activated protein kinase (AMPK). AMPK suppresses anabolic pathways and contributes to reduced hepatic gluconeogenesis and improved metabolic regulation.

5. Intestinal effects

Metformin also acts in the gastrointestinal tract, where it can increase intestinal glucose utilization and influence incretin signaling, including GLP-1.

Metformin in the liver

Metformin is taken up into the hepatocyte via the OTC1 – organic cation transporter. Within the mitochondria metformin accumulates in the matrix and inhibits complex1 electron transfer chain NADH ubiquitin oxidoreductase (NADH), which promotes proton generation.

This inhibition reduces NADH oxidation and ultimately significantly alters ATP (adenosine three phosphate) production by ATP synthase. AMP and ADP will rise, but most importantly the ratio:

1. AMP to ATP
2. ADP to ATP

The change in cellular energy status activates several mechanisms, including AMPK-dependent pathways, while metformin also affects gluconeogenesis through AMPK-independent mechanisms, including inhibition of mitochondrial glycerol-3-phosphate dehydrogenase (mGPD).

AMPK

AMPK helps the cell respond to low energy availability. It:

1. Increases Glucose Uptake from the blood – as you burn glucose to produce ATPs;
2. Improves Glucose utilization – you need to break it down to get energy;
3. Suppresses hepatic gluconeogenesis — reducing the production of new glucose when cellular energy is limited.

AMPK also suppresses hepatic gluconeogenesis through the cAMP–PKA–CREB pathway.

AMPK phosphorylates PDE4B (3′,5′-cyclic phosphodiesterase 4B), increasing cAMP degradation and therefore ↓ cAMP.

The drop in cAMP leads to:

1. ↓ PKA activity
2. ↓ activation of CREB-dependent transcription
3. ↓ formation/activity of the CREB–CBP–CRTC2 transcriptional complex

As a result, transcription of key gluconeogenic genes is reduced, including:

1. Phosphoenolpyruvate carboxykinase (PEPCK)
2. Glucose-6-phosphatase (G6Pase)

Result: ↓ expression of key gluconeogenic enzymes → ↓ hepatic gluconeogenesis → ↓ glucose production by the liver.

AMPK can also suppress gluconeogenic gene expression through additional mechanisms. It can phosphorylate CREB-binding protein (CBP) and CRTC2, reducing the activity of the CREB–CBP–CRTC2 transcriptional complex. Phosphorylation of CRTC2 also reduces its translocation into the nucleus, keeping it in the cytoplasm.

In addition, AMPK can increase expression of small heterodimer partner (SHP), a transcriptional repressor that further inhibits gluconeogenic gene expression.

AMPK-independent mechanisms

The increase in AMP caused by metformin can also suppress gluconeogenesis independently of AMPK.

AMP allosterically inhibits fructose-1,6-bisphosphatase (FBP1), a key enzyme of gluconeogenesis. This provides a direct way for increased AMP to reduce glucose production by the liver and may contribute to the early glucose-lowering effect of metformin.

AMP also inhibits adenylate cyclase, reducing the production of cAMP in response to glucagon. Since glucagon normally increases cAMP and activates pathways that promote gluconeogenesis during fasting, lower cAMP reduces the expression of gluconeogenic enzymes.

Result: ↑ AMP → ↓ FBP1 activity + ↓ glucagon-induced cAMP → ↓ gluconeogenesis.

Skeletal muscle

In skeletal muscle, metformin-induced AMPK activation increases glucose uptake and utilization.

AMPK stimulates the translocation of GLUT4 (glucose transporter 4) to the plasma membrane, allowing more glucose to enter muscle cells. This is an important acute response to AMPK activation.

AMPK also increases PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), a transcriptional coactivator that regulates genes involved in mitochondrial function and energy metabolism. Through PGC-1α, longer-term adaptations include increased expression of GLUT4 and mitochondrial genes involved in glucose and fatty-acid metabolism.

AMPK also phosphorylates acetyl-CoA carboxylase 2 (ACC2), reducing malonyl-CoA levels. Malonyl-CoA normally inhibits carnitine palmitoyltransferase 1 (CPT1), which transports long-chain fatty acids into mitochondria. Therefore:

↑ AMPK → ↓ ACC2 activity → ↓ malonyl-CoA → ↑ fatty-acid entry into mitochondria → ↑ fatty-acid oxidation

Overall, these effects increase glucose uptake and promote the use of both glucose and fatty acids as energy substrates in skeletal muscle.

Mechanism in Adipose tissue

In adipocytes, insulin normally activates the PI3K/Akt signaling pathway, which promotes GLUT4 translocation to the cell membrane and allows glucose to enter the cell.

Impaired insulin signaling through the PI3K/Akt pathway can reduce GLUT4 translocation and contribute to insulin resistance.

Metformin can improve insulin signaling and glucose uptake in adipose tissue. Experimental studies suggest that metformin can enhance the PI3K/Akt/GLUT4 pathway, although this appears to be a downstream effect rather than its primary mechanism of action.

Metformin also affects lipid metabolism in adipose tissue. Through improved insulin sensitivity and AMPK-related effects, it can:

• ↑ fatty-acid oxidation
• ↓ lipogenesis
• ↓ triglyceride accumulation

Together with increased glucose uptake in skeletal muscle and adipose tissue, these effects improve glucose disposal and insulin sensitivity.

Intestine

The intestine is another important site of metformin action. Metformin increases glucose uptake and utilization by enterocytes, particularly through increased anaerobic glucose metabolism. This can increase intestinal glucose consumption and contribute to the glucose-lowering effect of metformin.

Increased intestinal glucose metabolism also produces more lactate. The intestine is therefore, together with the liver, an important site contributing to metformin-associated lactate production. Lactate is normally released into the circulation and can subsequently be taken up by the liver.

Metformin also affects GLP-1 (glucagon-like peptide-1) signaling. GLP-1 is produced by L cells in the intestine, particularly in the distal small intestine and colon. Studies suggest that metformin can increase GLP-1 secretion through several mechanisms, including effects on intestinal GLP-1 production, DPP-4 (dipeptidyl peptidase-4) activity, and the intestinal bile-acid pool.

The exact contribution of these mechanisms to the overall glucose-lowering effect of metformin is still being investigated.

Summary: How does metformin work?

Metformin has a complex and multifaceted mechanism of action, involving several organs, cellular pathways, and metabolic processes. Its effects are not explained by a single molecular target.

The AMPK pathway is one of the major mechanisms involved. By altering cellular energy metabolism, metformin increases the AMP/ATP and ADP/ATP ratios, creating a signal of reduced readily available cellular energy. This shifts cellular metabolism away from energy-consuming processes and toward energy production.

In the liver, this results in suppression of de novo glucose production (gluconeogenesis) through several pathways, including reduced activity and expression of key gluconeogenic enzymes.

In skeletal muscle and other peripheral tissues, metformin improves glucose uptake and utilization, helping cells use glucose as an energy substrate. It also affects fatty-acid metabolism and insulin sensitivity.

However, AMPK is only part of the picture. Metformin also acts through AMPK-independent mechanisms, including:

• direct inhibition of fructose-1,6-bisphosphatase (FBP1) by AMP;
• inhibition of glucagon-stimulated cAMP production;
• changes in cellular redox state through inhibition of mGPD;
• effects on mitochondrial metabolism;
• effects in the gastrointestinal tract, including increased intestinal glucose utilization and effects on GLP-1 signaling.

Therefore, the overall effect can be summarized as:

Metformin → altered cellular energy metabolism → ↓ hepatic glucose production + ↑ peripheral glucose utilization → ↓ blood glucose

The molecular biology of metformin is still being investigated, and new mechanisms continue to emerge.

Beyond glucose lowering

Metformin’s effects extend beyond glucose metabolism. Its ability to influence cellular energy metabolism, AMPK/mTOR signaling, mitochondrial function, inflammation, and other pathways has generated substantial interest in its potential anticancer effects. Research into metformin as a possible cancer-preventive or therapeutic agent is ongoing, but its role in cancer treatment has not been established as a general clinical indication.

Explore next: Metformin and cancer — why is an antidiabetic drug being investigated as an anticancer agent?